Javascript must be enabled to continue!
Development and characterization of a polyclonal antibody against rat liver mitochondrial overt carnitine palmitoyltransferase (CPT I). Distinction of CPT I from CPT II and of isoforms of CPT I in different tissues
View through CrossRef
The [3H]tetradecylglycidyl-CoA (TDG-CoA)-binding protein (Mr approx. 88,000) of purified outer membranes from rat liver mitochondria was identified by SDS/PAGE. The region in which it migrated was shown to contain another protein which stained strongly with periodic acid-Schiff reagent and could be removed from membrane extracts by incubation with Sepharose-concanavalin A. Amounts of TDG-CoA-binding protein were prepared from lectin-treated extracts using preparative SDS/PAGE and used to raise a polyclonal antibody in a sheep. The IgG fraction purified from this anti-serum reacted strongly with a protein of Mr approximately 88,000 on Western blots, and much more weakly with two other proteins of Mr approximately 76,000 and Mr approximately 53,000 in extracts of rat liver mitochondrial outer membranes. The crude IgG fraction and immunopurified IgG both removed carnitine palmitoyltransferase (CPT) I activity from very pure outer membrane extracts, suggesting that the TDG-CoA-binding protein against which the antiserum was raised also expresses CPT I activity. This was confirmed by the demonstration of a strong positive correlation between CPT I activity and the amount of immunoreactive protein of Mr approximately 88,000 in mitochondria prepared from rats in different physiological states. By contrast, the antibody did not react with CPT II either in mitochondria or in purified form. Similarly, an anti-(CPT II) antibody did not cross-react with CPT I on Western blots, proving conclusively that CPT I and CPT II are immunologically distinct proteins, as well as being of different functional molecular sizes [Zammit, Corstophine & Kelliher (1988) Biochem. J. 250, 415-420]. Immunoblots of mitochondrial proteins obtained from different tissues indicated that, of the rat tissues tested, only kidney cortex mitochondria contain the same isoform of CPT I as that in liver. Heart, skeletal muscle and brown adipose tissue mitochondria contain a slightly smaller isoform which was only weakly reactive with anti-(rat liver CPT I) antibody, indicating that these tissues contain a molecularly quite distinct isoenzyme. This would explain the previous observations that CPT I in these tissues has markedly different kinetic characteristics from the isoenzyme present in liver mitochondria.
Title: Development and characterization of a polyclonal antibody against rat liver mitochondrial overt carnitine palmitoyltransferase (CPT I). Distinction of CPT I from CPT II and of isoforms of CPT I in different tissues
Description:
The [3H]tetradecylglycidyl-CoA (TDG-CoA)-binding protein (Mr approx.
88,000) of purified outer membranes from rat liver mitochondria was identified by SDS/PAGE.
The region in which it migrated was shown to contain another protein which stained strongly with periodic acid-Schiff reagent and could be removed from membrane extracts by incubation with Sepharose-concanavalin A.
Amounts of TDG-CoA-binding protein were prepared from lectin-treated extracts using preparative SDS/PAGE and used to raise a polyclonal antibody in a sheep.
The IgG fraction purified from this anti-serum reacted strongly with a protein of Mr approximately 88,000 on Western blots, and much more weakly with two other proteins of Mr approximately 76,000 and Mr approximately 53,000 in extracts of rat liver mitochondrial outer membranes.
The crude IgG fraction and immunopurified IgG both removed carnitine palmitoyltransferase (CPT) I activity from very pure outer membrane extracts, suggesting that the TDG-CoA-binding protein against which the antiserum was raised also expresses CPT I activity.
This was confirmed by the demonstration of a strong positive correlation between CPT I activity and the amount of immunoreactive protein of Mr approximately 88,000 in mitochondria prepared from rats in different physiological states.
By contrast, the antibody did not react with CPT II either in mitochondria or in purified form.
Similarly, an anti-(CPT II) antibody did not cross-react with CPT I on Western blots, proving conclusively that CPT I and CPT II are immunologically distinct proteins, as well as being of different functional molecular sizes [Zammit, Corstophine & Kelliher (1988) Biochem.
J.
250, 415-420].
Immunoblots of mitochondrial proteins obtained from different tissues indicated that, of the rat tissues tested, only kidney cortex mitochondria contain the same isoform of CPT I as that in liver.
Heart, skeletal muscle and brown adipose tissue mitochondria contain a slightly smaller isoform which was only weakly reactive with anti-(rat liver CPT I) antibody, indicating that these tissues contain a molecularly quite distinct isoenzyme.
This would explain the previous observations that CPT I in these tissues has markedly different kinetic characteristics from the isoenzyme present in liver mitochondria.
Related Results
Carnitine Inborn Errors of Metabolism
Carnitine Inborn Errors of Metabolism
Carnitine plays essential roles in intermediary metabolism. In non-vegetarians, most of carnitine sources (~75%) are obtained from diet whereas endogenous synthesis accounts for ar...
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED]Product Name - Bridport Health Ingredients - Milk Thistle, Beetroot, Artichoke Extract & More. Category - Liver Support Supplement Main Benefits - Helps Protect The ...
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED]Depiction • Where to Get Bottle Online –Click Here • Item Name -Bridport Health Liver • Aftereffects - No Major Side Effects • Classification - Health • Accessibility -O...
SGMS1-AS1/MicroRNA-106a-5p/CPT2 Axis as a Novel Target for Regulating Lactate Metabolism in Colon Cancer
SGMS1-AS1/MicroRNA-106a-5p/CPT2 Axis as a Novel Target for Regulating Lactate Metabolism in Colon Cancer
Purpose
The malignant transformation of cells can lead to aerobic glycolysis, an important form of metabolic reprogramming in colon cancer cells, which can caus...
Progression of Cisplatin-Induced Nephrotoxicity in a Carnitine-Depleted Rat Model
Progression of Cisplatin-Induced Nephrotoxicity in a Carnitine-Depleted Rat Model
<i>Background:</i> This study has been initiated to investigate whether endogenous carnitine depletion and/or carnitine deficiency is an additional risk factor and/or a...
Disorders of carnitine transport and the carnitine cycle
Disorders of carnitine transport and the carnitine cycle
Abstract
Carnitine plays an essential role in the transfer of long‐chain fatty acids across the inner mitochondrial membrane. This transfer requires enzymes and t...
Role of carnitine in regulation of hypoglycemia-induced hypertension and cardiac hypertrophy
Role of carnitine in regulation of hypoglycemia-induced hypertension and cardiac hypertrophy
Abstract
Background: Cardiovascular disease is a leading cause of death in diabetic patients. Hyperglycemia and iatrogenic hypoglycemia exacerbate several pathogenic mechan...
Carnitine Metabolism in Patients With Chronic Liver Disease
Carnitine Metabolism in Patients With Chronic Liver Disease
Carnitine metabolism was studied in 79 patients with chronic liver disease, including 22 patients with noncirrhotic liver disease and 57 patients with different types of cirrhosis ...

